What's happening
This bill requires sponsors and providers of clinical trials applying for state grants in New York to publicly post detailed information about those trials online.
Why it matters
Greater transparency for clinical trials using public funds. By requiring detailed public disclosure of sponsors, methods, and adverse effects, the bill aims to ensure accountability and allow the public to better understand how state grant money is being used in medical research.
Informed participation and community trust. Potential participants and the broader community will have easier access to critical information about clinical trials, including risks, purpose, and sponsors, which can help individuals make more informed decisions and build public trust in research practices.
Enhanced oversight and ethical standards. Mandating that both the Department of Health and healthcare providers post comprehensive trial details may deter unethical practices, improve oversight, and align New York’s clinical trial process with best practices for openness and safety.
Potential impact on research competitiveness and compliance. Researchers and sponsors seeking state grants must meet these transparency requirements, which could affect how trials are designed, reported, and funded, possibly influencing which institutions and companies choose to conduct research in New York.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Require Clinical Trial Transparency
Plain English, a few words. Used as the page title.
Sponsors
1 Co-sponsor
History
- Referred to health
- Referred to health
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Make Clinical Trials Public
In Assembly Committee · Health · Sponsor Michaelle C. Solages
Full text
2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
1523
2023-2024 Regular Sessions
IN SENATE
January 12, 2023
Introduced by Sens. PERSAUD, HOYLMAN-SIGAL -- read twice and ordered printed, and when printed to be committed to the Committee on Health
AN ACT to amend the public health law, in relation to requiring clinical trials that apply for state grant funding to make certain information about such clinical trials public
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Article 2 of the public health law is amended by adding a new title 9 to read as follows:
TITLE 9
CLINICAL TRIALS Section 269-b. Definitions.
269-c. Grant requirements.
269-d. Posting requirements.
§ 269-b. Definitions. For purposes of this title:
1. "clinical trial" shall have the same meaning as set forth in subdivision two-b of section forty-nine hundred of this chapter.
2. "health care provider" shall mean a practitioner in an individual practice, group practice, partnership, professional corporation or other authorized form of association, a hospital or other health care institution issued an operating certificate pursuant to this chapter or the mental hygiene law, a certified home health agency or a licensed home care services agency, and any other purveyor of health or health related items or services including but not limited to a clinical laboratory, a physiological laboratory, a pharmacy, a purveyor of x-ray or imaging services, a purveyor of physical therapy services, a purveyor of health or health related supplies, appliances or equipment, or an ambulance service.
§ 269-c. Grant requirements. 1. Following the effective date of this section, the commissioner shall require any sponsor of a clinical trial in this state, including but not limited to, a pharmaceutical drug
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD02577-01-3
manufacturer, pharmaceutical drug wholesaler, academic medical center, voluntary group, federal agency or health care provider, that applies for a state grant to conduct such clinical trial, to conspicuously post certain information about such clinical trial on the department's website.
2. To the extent disclosure is permitted under federal law, the information posted in accordance with subdivision one of this section shall include, but shall not be limited to, the following:
(a) the name of all clinical trial sponsors, funders and manufacturers, including the name and contact information, as well as the institutional affiliation, of all sponsors, co-sponsors and administrators;
(b) a summary of the purpose of the clinical trial, including, but not limited to: (i) the name of the pharmaceutical drug being tested and its active ingredients, if applicable; (ii) the type of clinical trial to be conducted; (iii) the overall design of the study, including the statistical method to be employed; (iv) the status or phase type of the trial; (v) the inclusion and exclusion criteria; (vi) the treatment methods used; (vii) all hypotheses tested by the trial; and (viii) the medical condition or conditions being studied;
(c) the start date and end date of the clinical trial; and
(d) information pertaining to the clinical trial, including, but not limited to potential adverse effects of the pharmaceutical drug or biological product associated with the clinical trial.
3. The commissioner shall promulgate rules and regulations as deemed necessary to aid in the collection and posting of the clinical trial information required pursuant to this section and shall monitor the department's website for compliance with the requirements of this section.
§ 269-d. Posting requirements. 1. Following the effective date of this section, the commissioner shall require any health care provider offering a clinical trial in this state to conspicuously post certain information about such clinical trial on their website.
2. To the extent disclosure is permitted under federal law, the information posted in accordance with subdivision one of this section shall include, but shall not be limited to, the following:
(a) the therapeutic intent of the clinical trial;
(b) the name of all clinical trial sponsors, funders and manufacturers, including the name and contact information, as well as the institutional affiliation, of all sponsors, co-sponsors and administrators;
(c) a summary of the purpose of the clinical trial, including, but not limited to: (i) the name of the pharmaceutical drug being tested and its active ingredients, if applicable; (ii) the type of clinical trial to be conducted; (iii) the overall design of the study, including the statistical method to be employed; (iv) the status or phase type of the trial; (v) the inclusion and exclusion criteria; (vi) the treatment methods used; (vii) all hypotheses tested by the trial; and (viii) the medical condition or conditions being studied;
(d) the start date and end date of the clinical trial; and
(e) information pertaining to the clinical trial, including, but not limited to potential adverse effects associated with the clinical trial.
§ 2. This act shall take effect immediately.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the public health law, in relation to requiring clinical trials that apply for state grant funding to make certain information about such clinical trials public
Purpose or general idea of bill
This bill requires clinical trials that apply for state grant funding to make certain information about such clinical trials public
Summary of specific provisions
Section 1 Contains clinical trial definition, grant, and posting requirements. Section 2. Provides for the effective date.
Justification
Obligating clinical trials to post information on their website is necessary to best suit the medical needs of patients and increase trans- parency. According to a study published by the National Library of Medi- cine, only about 41 percent of clinical trials are posted on time, as mandated by the Food and Drug Administration Amendments Act of 2007. Section 801 of the act required "applicable clinical trial" (ACT) to register their trials if they were initiated or ongoing after September 27th, 2007, were controlled clinical investigations (besides phase 1 investigations) of any Food and Drug-related drug or biological product. The act also required certain FDA-regulated medical devices to register their studies.
This delay in posting information regarding clinical trials hurts both doctors and patients, as they are not informed of benefits, side effects, target groups, and specific goals of the clinical trials. Therefore, they cannot determine if a drug or treatment is a viable option for them to use to deal with their illness. Clinical trials' lack of representation and transparency leads to less than adequate medical treatment. According to the Association of Clinical Research Profes- sionals, minorities are vastly underrepresented in clinical trials. African Americans make up only 5 percent of trial participants and Hispanics make up less than 1 percent of trials participants. Race is not the only factor showing a disparity between groups of people. The ACRP also finds that patients with annual incomes of less than $50,000 are 27 percent less likely to participate in clinical trials because they cannot find time due to their inability to get away from work, as they need a constant source of income. Because minorities and those in dire socioeconomic positions are not involved in clinical trials, there is no concrete evidence that the tested treatment will help deal with their medical issues.
The ACRP states how 5-Fluorouracil, a drug used for chemotherapy, can cause hematologic toxicities like leukopenia and anemia. The drug caused toxicities to occur more frequently in minority groups than Caucasian people. The clinical trials for the drug were composed of mostly Cauca- sian people, thus leading to inadequate results, as the effects the drug would have on minority groups were never fully tested. The lack of minority representation in clinical trials has shown that not involving minority groups in studies can further harm the health of minority groups.
By requiring conspicuous posts to be on clinical trials' websites, we allow the public to inform themselves of the specifics of medical trials so patients have the best and most clear treatments available. Informa- tion such as the stage and type of trial, active ingredients in drugs, and statistics of trials are all clear information that will make clin- ical trials more transparent and helpful.
This bill aims to increase the transparency between clinical trials and the general public to have better treatment available for patients.
Prior legislative history
2022: S8190 Referred to Health
Fiscal implications
None
Effective date
The act shall take effect immediately.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.